Top Markets
Coin of the day
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
株式のランク #25527
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
株価
$9.81
最終同期: 2025-03-18
時価総額
$48.68M
変化(1日)
1.55%
変化(1年)
0.00%
US
取引 AlloVir, Inc. (ALVR)

カテゴリー

AlloVir, Inc.(ALVR)の配当利回りの履歴
AlloVir, Inc.(銘柄コード: ALVR)の配当利回り(TTM)は2023-12-31時点で0.00%です。
過去5年間の平均配当利回り: 0.00%
AlloVir, Inc.(ALVR)の2022から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
類似企業または競合他社の配当利回り(TTM)